Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke
- 448 Downloads
Percutaneous approaches to left atrial appendage (LAA) closure are being developed for stroke prophylaxis in atrial fibrillation patients as an alternative to warfarin. Non-randomized clinical trials suggested that the first of these devices, the percutaneous left atrial appendage transcatheter occlusion (PLAATO) device, is safe and reduces stroke risk. Percutaneous closure has the potential limitation of incomplete exclusion of LAA from the systemic circulation, which could potentially lead to thrombus formation and stroke. This study investigated the interaction between residual blood flow in the LAA after percutaneous closure with PLAATO and risk of stroke.
Methods and results
Data from the PLAATO trial current as of July 2010 was used for this analysis (n = 22). Mechanical occlusion using the PLAATO device was used in 22 patients (age 68 ± 5, CHADS2 score = 3.03 ± 0.6). Warfarin and clopidogrel were stopped during follow-up in all but one patient due to development of pulmonary emboli. After an average follow-up of 58 ± 9 months, four out of 22 patients (16.7%) developed a new ischemic stroke/TIA, translating to an annualized embolic rate of 3.63%. There were no differences in the demographics (age, sex, and CHADS2 score) among patients with and without stroke. Cardiac CT documented peri-device leak in three out of four patients with stroke and in seven out of nine (75% vs. 77%, p = 0.706) patients without stroke that agreed to have a follow-up cardiac CT (Chi squared with Yates correction for this interaction = 0.012, p = 0.912). TEE corroborated these results but failed to identify peri-device leak in three patients without stroke.
The main finding of our analysis suggests that in long-term follow-up, residual flow after LAA occlusion with the PLAATO device, as documented by cardiac CT, is ubiquitous but is not associated with an increased risk of stroke.
KeywordsLeft atrial appendage Occlusion device Atrial fibrillation Stroke PLAATO Watchman
Conflict of interest
- 1.Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 114, 119–125.PubMedCrossRefGoogle Scholar
- 2.Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., et al. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): A randomised controlled trial. Lancet, 367, 1903–1912.PubMedCrossRefGoogle Scholar
- 8.Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., et al. (2009). Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet, 374, 534–542.PubMedCrossRefGoogle Scholar
- 10.Ostermayer, S. H., Reisman, M., Kramer, P. H., Matthews, R. V., Gray, W. A., Block, P. C., et al. (2005). Percutaneous left atrial appendage transcatheter occlusion (plaato system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: Results from the international multi-center feasibility trials. Journal of the American College of Cardiology, 46, 9–14.PubMedCrossRefGoogle Scholar
- 14.Katz, E. S., Tsiamtsiouris, T., Applebaum, R. M., Schwartzbard, A., Tunick, P. A., & Kronzon, I. (2000). Surgical left atrial appendage ligation is frequently incomplete: A transesophageal echocardiograhic study. Journal of the American College of Cardiology, 36, 468–471.PubMedCrossRefGoogle Scholar
- 15.Garcia-Fernandez, M. A., Perez-David, E., Quiles, J., Peralta, J., Garcia-Rojas, I., Bermejo, J., et al. (2003). Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: A transesophageal echocardiographic study. Journal of the American College of Cardiology, 42, 1253–1258.PubMedCrossRefGoogle Scholar
- 16.Block, P. C., Burstein, S., Casale, P. N., Kramer, P. H., Teirstein, P., Williams, D. O., et al. (2009). Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the plaato (percutaneous left atrial appendage transcatheter occlusion) study. JACC. Cardiovascular Interventions, 2, 594–600.PubMedCrossRefGoogle Scholar
- 17.Mahaffey KW R-Ai. Rivaroxaban once-daily oral direct factor xa inhibition compared with vitamin k antagonism for the prevention of stroke and embolism trial in atrial fibrillation. American Heart Association. 2010.Google Scholar
- 19.Bayard, Y. L., Omran, H., Neuzil, P., Thuesen, L., Pichler, M., Rowland, E., et al. (2010). Plaato (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: Results from the european plaato study. EuroIntervention, 6, 220–226.PubMedCrossRefGoogle Scholar
- 21.Blackshear, J. L., Zabalgoitia, M., Pennock, G., Fenster, P., Strauss, R., Halperin, J., et al. (1999). Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. Spaf tee investigators. Stroke prevention and atrial fibrillation. Transesophageal echocardiography. The American Journal of Cardiology, 83, 453–455. A459.PubMedCrossRefGoogle Scholar